Peptides and Methods for Treating Disease
AssigneeOp-T LLC
InventorsDavid Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
Life of this patent
Estimating the term…
Loading patent…
AssigneeOp-T LLC
InventorsDavid Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
Estimating the term…
Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to β-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.
A peptide less than 20 amino acids in length, for the treatment of diabetes, said peptide comprising an amino acid sequence selected from the group of:
(canceled)
(canceled)
-9. (canceled)
-14. (canceled)
A method for preventing, modulating, and/or reducing diabetes mellitus in a subject, the method comprising-administering a peptide selected from the group of:
-20. (canceled)
(canceled)
-29. (canceled)
(canceled)
(canceled)
(canceled)
-48. (canceled)
A pharmaceutical composition for the treatment of diseases selected from the group of type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosa, chronic obstructive pulmonary disease, atherosclerosis, and/or acute respiratory distress syndrome, comprising at least one bioactive peptide selected from SEQ ID NOs:
(canceled)
(canceled)
Dependencies are inferred from the claim text.